Total cases for the three months ended September 30, 2015 were 4,418, representing an increase of 2,769 cases or 168% from 1,649 cases in the prior corresponding 2014 period. Net income attributable to Nobilis for the three months ended September 30, 2015 was $10.9 million compared with a net income of $1.2 million from the prior corresponding 2014 period.

The increase in total revenues resulted in Nobilis having an Adjusted EBITDA of $9.7 million, for the three months ended September 30, 2015 compared with $1.9 million from the prior corresponding 2014 period, representing an increase of 398%.

See below for a reconciliation of GAAP and non-GAAP financial results.

Nine Months Results

Total revenues for the nine months ended September 30, 2015 totaled $139.2 million, an increase of $94.8 million or 214%, compared to $44.4 million from the prior corresponding 2014 period.

Total cases for the nine months ended September 30, 2015 were 12,549, representing an increase of 162% from the prior corresponding 2014 period. Net income attributable to Nobilis for the nine months ended September 30, 2015 was $6.0 million compared with a net income of $1.7 million from the prior corresponding 2014 period.

Adjusted EBITDA for the nine months ended September 30, 2015 was $21.0 million as compared with $2.9 million from the prior corresponding 2014 period, representing an increase of 615%.

Cash flows provided by operating activities in the nine months ended September 30, 2015 were $2.8 million, which represented a $1.7 million decrease compared to the prior corresponding 2014 period, which provided $4.5 million in cash flows from operating activities.

At September 30, 2015, Nobilis had consolidated net working capital of $55.8 million, including cash of $21.1 million. This compares with $22.3 million and $7.6 million, respectively, as of December 31, 2014.

Conference Call Information

Nobilis will host a conference call on Thursday, January 14, 2016, at 8 a.m. CST to discuss its financial results for the third quarter ended September 30, 2015. To participate in the conference call, please dial (855) 789-8159 in the US and Canada, and (631) 485-4889 internationally. Please enter passcode 25541107. There will be a livestream of the conference call available at: http://edge.media-server.com/m/p/b7t6q95q.

Restatement and Management Cease Trade Order

Nobilis also announced that it has completed the Restatement Reports, which are in line with the information contained in its press release dated January 5, 2016. Restatement Reports are being filed in conjunction with the Form 10-Q for the three and nine months ended September 30, 2015.

The Company expects that the Ontario Securities Commission, as principal Canadian regulator for the Company, will lift the management cease trade order issued on Friday, December 4, 2015, because the Company filed the Restatement Reports today as well as its unaudited interim financial statements for the three and nine months ended September 30, 2015, the related management's discussion and analysis and CEO and CFO certificates.

Safe Harbor

This press release contain certain forward-looking statements within the meaning of Canadian and United States securities laws, including the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts and may be identified by the use of words such as "may," "believe," "will," "expect," "project," "estimate," "anticipate," "plan" or "continue." These forward-looking statements are based on current plans and expectations and are subject to a number of risks, uncertainties and other factors which could significantly affect current plans and expectations and our future financial condition and results. These factors, which could cause actual results, performance and achievements to differ materially from those anticipated, include, but are not limited to the risk that we may face challenges managing our new Marketing Segment and may not realize anticipated benefits; our ability to successfully maintain effective internal controls over financial reporting; our ability to implement our business strategy, manage the growth in our business, and integrate acquired businesses; the risk of litigation and investigations, and liability claims for damages and other expenses not covered by insurance; the risk that payments from third-party payers, including government healthcare programs, may decrease or not increase as costs increase; adverse developments affecting the medical practices of our physician limited partners; our ability to maintain favorable relations with our physician limited partners; our ability to grow revenues by increasing case and procedure volume while maintaining profitability at the Nobilis Facilities; failure to timely or accurately bill for services; our ability to compete for physician partners, patients and strategic relationships; the risk of changes in patient volume and patient mix; the risk that laws and regulations that regulate payments for medical services made by government healthcare programs could cause our revenues to decrease; the risk that contracts are cancelled or not renewed or that we are not able to enter into additional contracts under terms that are acceptable to us; and the risk of potential decreases in our reimbursement rates. The foregoing are significant factors we think could cause our actual results to differ materially from expected results. However, there could be additional factors besides those listed herein that also could affect us in an adverse manner.

We have not undertaken any obligation to publicly update or revise any forward-looking statements. All of our forward-looking statements speak only as of the date of the document in which they are made or, if a date is specified, as of such date. Subject to an mandatory requirements of applicable law, we disclaim any obligation or undertaking to provide any updates or revisions to any forward-looking statement to reflect any change in our expectations or any changes in events, conditions, circumstances or information on which the forward-looking statement is based. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing factors and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014, filed on April 2, 2015, as updated by other filings with the Securities and Exchange Commission.

About Nobilis Health Corp.
Nobilis utilizes innovative direct-to-patient marketing focused on a specified set of procedures that are performed at our centers by local physicians. Currently, Nobilis owns or manages four surgical hospitals and five ASCs, partners with an additional 31 facilities throughout the country, and markets six independent brands.

¹Adjusted EBITDA is defined as earnings before interest, income taxes, depreciation and amortization, non-cash compensation, expenses, acquisition expenses and change in fair value of warrant and stock option liabilities. Adjusted EBITDA should not be considered a measure of financial performance under generally accepted accounting principles. Items excluded from adjusted EBITDA are significant components in understanding and assessing financial performance. Adjusted EBITDA is an analytical indicator used by management and the health care industry to evaluate company performance, allocate resources and measure leverage and debt service capacity. Adjusted EBITDA should not be considered in isolation or as an alternative to net income, cash flows generated by operations, investing or financing activities, or other financial statement data presented in the consolidated financial statements as indicators of financial performance or liquidity. Because adjusted EBITDA is not a measurement determined in accordance with generally accepted accounting principles and is thus susceptible to varying calculations, adjusted EBITDA as presented may not be comparable to other similarly titled measures of other companies. Net income attributable to Nobilis Health Corp. common shareholders is the financial measure calculated and presented in accordance with generally accepted accounting principles that is most comparable to adjusted EBITDA as defined.